India foresees spread of generics seizures via ACTA

The drug seizure agreement between India and the EU, intended to stop European customs officials from seizing legitimate generics on their way to Africa and Latin America by claiming patent infringement, may be for naught. And India may be facing the same issue on a larger scale in the likely soon-to-be enacted Anti-Counterfeiting Trade Agreement. ACTA still promotes an EU-style legal regime that would facilitate cross-border seizures of legitimate and lawful generic medicines that transit through any member country, says one law professor. Article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.